{
    "id": 5517,
    "name": "stomach carcinoma",
    "source": "DOID",
    "definition": "A stomach cancer that is located_in the stomach. [url:http\\://en.wikipedia.org/wiki/Stomach_cancer]",
    "currentPreferredTerm": null,
    "lastUpdateDateFromDO": "03/24/2020",
    "altIds": [
        
    ],
    "termId": "DOID:5517",
    "evidence": [
        {
            "id": 562,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Tivantinib (ARQ197) demonstrated efficacy in previously treated patients with metastatic gastric cancer (PMID: 24337769).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 636,
                "therapyName": "Tivantinib",
                "synonyms": null
            },
            "indication": {
                "id": 5517,
                "name": "stomach carcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 334,
                    "pubMedId": 24337769,
                    "title": "A phase II trial of a selective c-Met inhibitor tivantinib (ARQ 197) monotherapy as a second- or third-line therapy in the patients with metastatic gastric cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24337769"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 799,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In preclinical studies, a MET amplified, gastric carcinoma cell over expressing Met was sensitive to K252a treatment in both culture and mouse model experiments (PMID: 12118367).",
            "molecularProfile": {
                "id": 1066,
                "profileName": "MET amp MET over exp"
            },
            "therapy": {
                "id": 1088,
                "therapyName": "K252a",
                "synonyms": null
            },
            "indication": {
                "id": 5517,
                "name": "stomach carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 451,
                    "pubMedId": 12118367,
                    "title": "K252a inhibits the oncogenic properties of Met, the HGF receptor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/12118367"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1770,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, S-49076 inhibited Met activation, resulting in growth inhibition of gastric carcinoma cells harboring MET activating mutations in culture and in cell line xenograft models (PMID: 23804704).",
            "molecularProfile": {
                "id": 2096,
                "profileName": "MET act mut"
            },
            "therapy": {
                "id": 2158,
                "therapyName": "S-49076",
                "synonyms": null
            },
            "indication": {
                "id": 5517,
                "name": "stomach carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2007,
                    "pubMedId": 23804704,
                    "title": "S49076 is a novel kinase inhibitor of MET, AXL, and FGFR with strong preclinical activity alone and in association with bevacizumab.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23804704"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1771,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, S-49076 inhibited Met activation, resulting in growth inhibition of gastric carcinoma cells harboring FGFR2 activating mutations in culture and in cell line xenograft models (PMID: 23804704).",
            "molecularProfile": {
                "id": 1219,
                "profileName": "FGFR2 act mut"
            },
            "therapy": {
                "id": 2158,
                "therapyName": "S-49076",
                "synonyms": null
            },
            "indication": {
                "id": 5517,
                "name": "stomach carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2007,
                    "pubMedId": 23804704,
                    "title": "S49076 is a novel kinase inhibitor of MET, AXL, and FGFR with strong preclinical activity alone and in association with bevacizumab.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23804704"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2916,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Tucatinib (ARRY-380) inhibited tumor growth in a ERBB2 (HER2)-positive gastric carcinoma cell line xenograft model (Cancer Res April 15, 2012 72:852).",
            "molecularProfile": {
                "id": 1187,
                "profileName": "ERBB2 positive"
            },
            "therapy": {
                "id": 639,
                "therapyName": "Tucatinib",
                "synonyms": null
            },
            "indication": {
                "id": 5517,
                "name": "stomach carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3525,
                    "pubMedId": null,
                    "title": "Abstract 852: ARRY-380, a potent, small molecule inhibitor of ErbB2, increases survival in intracranial ErbB2+ xenograft models in mice",
                    "url": "http://cancerres.aacrjournals.org/content/72/8_Supplement/852"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3526,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a gastric carcinoma cell line harboring MET amplification treated with PF-04217903 eventually developed resistance due to acquisition of the fusion SND1-BRAF, in culture (PMID: 22745804).",
            "molecularProfile": {
                "id": 13346,
                "profileName": "SND1 - BRAF MET amp"
            },
            "therapy": {
                "id": 864,
                "therapyName": "PF-04217903",
                "synonyms": null
            },
            "indication": {
                "id": 5517,
                "name": "stomach carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3751,
                    "pubMedId": 22745804,
                    "title": "A novel SND1-BRAF fusion confers resistance to c-Met inhibitor PF-04217903 in GTL16 cells through [corrected] MAPK activation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22745804"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3527,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a gastric cancer cell line harboring MET amplification and SND1-BRAF was sensitive to the combination of PF-04880594 and PF-0461903 in culture (PMID: 22745804).",
            "molecularProfile": {
                "id": 13346,
                "profileName": "SND1 - BRAF MET amp"
            },
            "therapy": {
                "id": 3152,
                "therapyName": "PF-0461903 + PF-04880594",
                "synonyms": null
            },
            "indication": {
                "id": 5517,
                "name": "stomach carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3751,
                    "pubMedId": 22745804,
                    "title": "A novel SND1-BRAF fusion confers resistance to c-Met inhibitor PF-04217903 in GTL16 cells through [corrected] MAPK activation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22745804"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3558,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a gastric carcinoma cell line harboring CDKN2A R80* was sensitive to Ibrance (palbociclib) both in culture and in cell line xenograft models (PMID: 26380006, PMID: 20952405).",
            "molecularProfile": {
                "id": 7936,
                "profileName": "CDKN2A R80*"
            },
            "therapy": {
                "id": 850,
                "therapyName": "Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 5517,
                "name": "stomach carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3810,
                    "pubMedId": 26380006,
                    "title": "CDK4/6 inhibitor suppresses gastric cancer with CDKN2A mutation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26380006"
                },
                {
                    "id": 3811,
                    "pubMedId": 20952405,
                    "title": "COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20952405"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4725,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, SST0116CL1 inhibited tumor growth in cell line xenograft models of gastric carcinoma (PMID: 25096516).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 3602,
                "therapyName": "SST0116CL1",
                "synonyms": null
            },
            "indication": {
                "id": 5517,
                "name": "stomach carcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 4679,
                    "pubMedId": 25096516,
                    "title": "Preclinical antitumor activity of SST0116CL1: a novel heat shock protein 90 inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25096516"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 7727,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, EMD 1214063 induced tumor regression in mouse cell line xenograft models of gastric carcinoma harboring MET amplification (PMID: 23553846).",
            "molecularProfile": {
                "id": 1629,
                "profileName": "MET amp"
            },
            "therapy": {
                "id": 726,
                "therapyName": "EMD 1214063",
                "synonyms": null
            },
            "indication": {
                "id": 5517,
                "name": "stomach carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 336,
                    "pubMedId": 23553846,
                    "title": "EMD 1214063 and EMD 1204831 constitute a new class of potent and highly selective c-Met inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23553846"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8247,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, SYD985 decreased survival of a ERBB2 (HER2)-positive gastric carcinoma cell line in culture (PMID: 25589493).",
            "molecularProfile": {
                "id": 1187,
                "profileName": "ERBB2 positive"
            },
            "therapy": {
                "id": 4539,
                "therapyName": "SYD985",
                "synonyms": null
            },
            "indication": {
                "id": 5517,
                "name": "stomach carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6587,
                    "pubMedId": 25589493,
                    "title": "The Preclinical Profile of the Duocarmycin-Based HER2-Targeting ADC SYD985 Predicts for Clinical Benefit in Low HER2-Expressing Breast Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25589493"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8404,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, PRN1371 inhibited proliferation of FGFR2 amplified gastric carcinoma cells in culture and tumor growth in cell line xenograft models (PMID: 28978721).",
            "molecularProfile": {
                "id": 3147,
                "profileName": "FGFR2 amp"
            },
            "therapy": {
                "id": 3583,
                "therapyName": "PRN1371",
                "synonyms": null
            },
            "indication": {
                "id": 5517,
                "name": "stomach carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10753,
                    "pubMedId": 28978721,
                    "title": "The Irreversible Covalent Fibroblast Growth Factor Receptor Inhibitor PRN1371 Exhibits Sustained Inhibition of FGFR after Drug Clearance.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28978721"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8453,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, FGFR2 amplified gastric carcinoma cell lines were not sensitive to RO4987655 in culture (PMID: 26438159).",
            "molecularProfile": {
                "id": 3147,
                "profileName": "FGFR2 amp"
            },
            "therapy": {
                "id": 903,
                "therapyName": "RO4987655",
                "synonyms": null
            },
            "indication": {
                "id": 5517,
                "name": "stomach carcinoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 4382,
                    "pubMedId": 26438159,
                    "title": "ERK Signal Suppression and Sensitivity to CH5183284/Debio 1347, a Selective FGFR Inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26438159"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8471,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, FGFR2 amplified gastric carcinoma cell lines were not sensitive to RO5126766 in culture (PMID: 26438159).",
            "molecularProfile": {
                "id": 3147,
                "profileName": "FGFR2 amp"
            },
            "therapy": {
                "id": 2011,
                "therapyName": "RO5126766",
                "synonyms": null
            },
            "indication": {
                "id": 5517,
                "name": "stomach carcinoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 4382,
                    "pubMedId": 26438159,
                    "title": "ERK Signal Suppression and Sensitivity to CH5183284/Debio 1347, a Selective FGFR Inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26438159"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8494,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Debio 1347 did not inhibit tumor growth in cell line xenograft models of ERBB2 (HER2) amplified gastric carcinoma (PMID: 26438159).",
            "molecularProfile": {
                "id": 531,
                "profileName": "ERBB2 amp"
            },
            "therapy": {
                "id": 1014,
                "therapyName": "Debio 1347",
                "synonyms": null
            },
            "indication": {
                "id": 5517,
                "name": "stomach carcinoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 4382,
                    "pubMedId": 26438159,
                    "title": "ERK Signal Suppression and Sensitivity to CH5183284/Debio 1347, a Selective FGFR Inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26438159"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8496,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Debio 1347 inhibited tumor growth in cell line xenograft models of FGFR2 amplified gastric carcinoma (PMID: 26438159).",
            "molecularProfile": {
                "id": 3147,
                "profileName": "FGFR2 amp"
            },
            "therapy": {
                "id": 1014,
                "therapyName": "Debio 1347",
                "synonyms": null
            },
            "indication": {
                "id": 5517,
                "name": "stomach carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4382,
                    "pubMedId": 26438159,
                    "title": "ERK Signal Suppression and Sensitivity to CH5183284/Debio 1347, a Selective FGFR Inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26438159"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8962,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MGCD516 decreased tumor cell proliferation, tumor vascularization, and target phosphorylation in human stomach carcinoma cell line xenograft models (Cancer Research: April 15, 2013; Volume 73, Issue 8, Supplement 1, Abstract 930).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 1655,
                "therapyName": "MGCD516",
                "synonyms": null
            },
            "indication": {
                "id": 5517,
                "name": "stomach carcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 6811,
                    "pubMedId": null,
                    "title": "Preclinical characterization of MG516, a novel inhibitor of receptor tyrosine kinases involved in resistance to targeted therapies.",
                    "url": "http://cancerres.aacrjournals.org/content/73/8_Supplement/930"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 9468,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, EMD 1214063 inhibited Met phosphorylation and cell viability of Met over-expressing gasric carcinoma cell lines in culture, regardless of their TP53 status (PMID: 26358474).",
            "molecularProfile": {
                "id": 5392,
                "profileName": "MET over exp"
            },
            "therapy": {
                "id": 726,
                "therapyName": "EMD 1214063",
                "synonyms": null
            },
            "indication": {
                "id": 5517,
                "name": "stomach carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7198,
                    "pubMedId": 26358474,
                    "title": "Impact of p53 Status on Radiosensitization of Tumor Cells by MET Inhibition-Associated Checkpoint Abrogation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26358474"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9470,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, shRNA knock-down of Tp53 in Met over-expressing gastric carcinoma cells enhanced sensitivity to the combination of EMD 1214063 and radiation in culture (PMID: 26358474).",
            "molecularProfile": {
                "id": 26857,
                "profileName": "MET over exp TP53 dec exp"
            },
            "therapy": {
                "id": 5024,
                "therapyName": "EMD 1214063 + Radiotherapy",
                "synonyms": null
            },
            "indication": {
                "id": 5517,
                "name": "stomach carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7198,
                    "pubMedId": 26358474,
                    "title": "Impact of p53 Status on Radiosensitization of Tumor Cells by MET Inhibition-Associated Checkpoint Abrogation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26358474"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11701,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, KO-947 inhibited Erk signaling and induced tumor regression in patient-derived xenograft models of BRAF-mutant gastric carcinoma (Cancer Res 2017;77(13 Suppl):Abstract nr 5168).",
            "molecularProfile": {
                "id": 465,
                "profileName": "BRAF mutant"
            },
            "therapy": {
                "id": 5747,
                "therapyName": "KO-947",
                "synonyms": null
            },
            "indication": {
                "id": 5517,
                "name": "stomach carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 9707,
                    "pubMedId": null,
                    "title": "KO-947, a potent ERK inhibitor with robust preclinical single agent activity in MAPK pathway dysregulated tumors",
                    "url": "http://cancerres.aacrjournals.org/content/77/13_Supplement/5168.short"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11702,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, KO-947 inhibited Erk signaling and induced tumor regression in patient-derived xenograft models of NRAS-mutant gastric carcinoma (Cancer Res 2017;77(13 Suppl):Abstract nr 5168).",
            "molecularProfile": {
                "id": 3,
                "profileName": "NRAS mutant"
            },
            "therapy": {
                "id": 5747,
                "therapyName": "KO-947",
                "synonyms": null
            },
            "indication": {
                "id": 5517,
                "name": "stomach carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 9707,
                    "pubMedId": null,
                    "title": "KO-947, a potent ERK inhibitor with robust preclinical single agent activity in MAPK pathway dysregulated tumors",
                    "url": "http://cancerres.aacrjournals.org/content/77/13_Supplement/5168.short"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11971,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, KO-947 inhibited Erk signaling and induced tumor regression in patient-derived xenograft models of KRAS-mutant gastric carcinoma (Cancer Res 2017;77(13 Suppl):Abstract nr 5168).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 5747,
                "therapyName": "KO-947",
                "synonyms": null
            },
            "indication": {
                "id": 5517,
                "name": "stomach carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 9707,
                    "pubMedId": null,
                    "title": "KO-947, a potent ERK inhibitor with robust preclinical single agent activity in MAPK pathway dysregulated tumors",
                    "url": "http://cancerres.aacrjournals.org/content/77/13_Supplement/5168.short"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16405,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, SAIT301 inhibited growth of patient-derived gastric carcinoma cells harboring a MET exon 14 skipping mutation in culture (PMID: 26375439).",
            "molecularProfile": {
                "id": 26413,
                "profileName": "MET del exon14"
            },
            "therapy": {
                "id": 8017,
                "therapyName": "SAIT301",
                "synonyms": null
            },
            "indication": {
                "id": 5517,
                "name": "stomach carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 14482,
                    "pubMedId": 26375439,
                    "title": "Gastrointestinal malignancies harbor actionable MET exon 14 deletions.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26375439"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16406,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Xalkori (crizotinib) inhibited growth of patient-derived gastric carcinoma cells harboring a MET exon 14 skipping mutation in culture (PMID: 26375439).",
            "molecularProfile": {
                "id": 26413,
                "profileName": "MET del exon14"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 5517,
                "name": "stomach carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 14482,
                    "pubMedId": 26375439,
                    "title": "Gastrointestinal malignancies harbor actionable MET exon 14 deletions.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26375439"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16407,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, PHA-665752 inhibited growth of patient-derived gastric carcinoma cells harboring a MET exon 14 skipping mutation in culture (PMID: 26375439).",
            "molecularProfile": {
                "id": 26413,
                "profileName": "MET del exon14"
            },
            "therapy": {
                "id": 2162,
                "therapyName": "PHA-665752",
                "synonyms": null
            },
            "indication": {
                "id": 5517,
                "name": "stomach carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 14482,
                    "pubMedId": 26375439,
                    "title": "Gastrointestinal malignancies harbor actionable MET exon 14 deletions.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26375439"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16408,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Cometriq (cabozantinib) inhibited growth of patient-derived gastric carcinoma cells harboring a MET exon 14 skipping mutation in culture (PMID: 26375439).",
            "molecularProfile": {
                "id": 26413,
                "profileName": "MET del exon14"
            },
            "therapy": {
                "id": 998,
                "therapyName": "Cabozantinib",
                "synonyms": null
            },
            "indication": {
                "id": 5517,
                "name": "stomach carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 14482,
                    "pubMedId": 26375439,
                    "title": "Gastrointestinal malignancies harbor actionable MET exon 14 deletions.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26375439"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "clinicalTrials": [
        {
            "nctId": "NCT01174121",
            "title": "Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 2291,
                    "therapyName": "Cyclophosphamide + Fludarabine",
                    "synonyms": null
                },
                {
                    "id": 1167,
                    "therapyName": "Aldesleukin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01183559",
            "title": "A Trial of ZD6474 (Zactima), Paclitaxel, Carboplatin, 5-Fluorouracil, and XRT Followed by Surgery",
            "phase": "Phase I",
            "recruitment": "Unknown status",
            "therapies": [
                {
                    "id": 2071,
                    "therapyName": "Carboplatin + Fluorouracil + Paclitaxel + Vandetanib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02065765",
            "title": "International Expanded Access Program to Provide Ramucirumab for the Treatment of Metastatic Gastric Cancer",
            "phase": "Phase II",
            "recruitment": "No longer available",
            "therapies": [
                {
                    "id": 886,
                    "therapyName": "Ramucirumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02274012",
            "title": "Trial of Afatinib in Combination With Weekly Paclitaxel in the Second Line Treatment of HER2 Amplified Advanced Gastric, Gastroesophageal Junction and Esophageal Cancer",
            "phase": "Phase II",
            "recruitment": "Withdrawn",
            "therapies": [
                {
                    "id": 2441,
                    "therapyName": "Afatinib + Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02344810",
            "title": "C-Met Inhibitor AMG 337, Oxaliplatin, Leucovorin Calcium, and Fluorouracil in Treating Patients With Advanced Stomach or Esophageal Cancer",
            "phase": "Phase Ib/II",
            "recruitment": "Withdrawn",
            "therapies": [
                {
                    "id": 1064,
                    "therapyName": "AMG 337",
                    "synonyms": null
                },
                {
                    "id": 1161,
                    "therapyName": "Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02488759",
            "title": "A Study to Investigate the Safety and Efficacy of Nivolumab in Virus-associated Tumors (CheckMate358)",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1312,
                    "therapyName": "Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02773524",
            "title": "A Study of Regorafenib in Refractory Advanced Gastro-Oesophageal Cancer (INTEGRATEII)",
            "phase": "Phase III",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 890,
                    "therapyName": "Regorafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02830594",
            "title": "Pembrolizumab and Palliative Radiation Therapy in Treating Patients With Metastatic Esophagus, Stomach, or Gastroesophageal Junction Cancer",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02892123",
            "title": "Trial of ZW25 in Patients With Advanced HER2-expressing Cancers",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8332,
                    "therapyName": "Capecitabine + ZW25",
                    "synonyms": null
                },
                {
                    "id": 6240,
                    "therapyName": "ZW25",
                    "synonyms": null
                },
                {
                    "id": 8333,
                    "therapyName": "Paclitaxel + ZW25",
                    "synonyms": null
                },
                {
                    "id": 8334,
                    "therapyName": "Vinorelbine + ZW25",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03008278",
            "title": "Olaparib and Ramucirumab in Treating Patients With Metastatic or Locally Recurrent Gastric or Gastroesophageal Junction Cancer That Cannot Be Removed by Surgery",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5165,
                    "therapyName": "Olaparib + Ramucirumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03076372",
            "title": "A Study Evaluating MM-310 in Patients With Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Unknown status",
            "therapies": [
                {
                    "id": 5758,
                    "therapyName": "MM-310",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03175224",
            "title": "CBT-101 Study for Advanced Solid Tumors and c-Met Dysregulation",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5963,
                    "therapyName": "CBT-101",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03288350",
            "title": "mDCF + Avelumab in Resectable Esophago-gastric Adenocarcinoma (EGA)",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1930,
                    "therapyName": "Cisplatin + Docetaxel + Fluorouracil",
                    "synonyms": null
                },
                {
                    "id": 3144,
                    "therapyName": "Avelumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03474640",
            "title": "Safety, Tolerability and Pharmacokinetics of an Anti-PD-1 Monoclonal Antibody in Subjects With Advanced Malignancies",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5891,
                    "therapyName": "Toripalimab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04096638",
            "title": "Evaluating Safety and Efficacy of SB 11285 Alone and in Combination With Nivolumab in Patients With Advanced Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8759,
                    "therapyName": "Nivolumab + SB 11285",
                    "synonyms": null
                },
                {
                    "id": 8758,
                    "therapyName": "SB 11285",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04140526",
            "title": "Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC",
            "phase": "Phase Ib/II",
            "recruitment": "Not yet recruiting",
            "therapies": [
                {
                    "id": 8898,
                    "therapyName": "ONC-392",
                    "synonyms": null
                },
                {
                    "id": 8899,
                    "therapyName": "ONC-392 + Pembrolizumab",
                    "synonyms": null
                }
            ]
        }
    ]
}